Eisai's Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson's Disease
This article was originally published in PharmAsia News
Executive Summary
Eisai has pushed back the filing of its novel AMPA receptor antagonist perampanel for Parkinson's disease from fiscal 2007 to fiscal fourth quarter 2008 (ended March 31, 2009) in the U.S. and Europe because the drug failed to show an efficacy benefit over placebo in a Phase III study, Eisai said Oct. 30